Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG.

Kidney Int. 2012 Mar;81(6):559-67. doi: 10.1038/ki.2011.371. Epub 2011 Nov 9.

2.
3.

Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.

Hollstein M, Moriya M, Grollman AP, Olivier M.

Mutat Res. 2013 Jul-Sep;753(1):41-9. doi: 10.1016/j.mrrev.2013.02.003. Epub 2013 Feb 17. Review.

4.

Aristolochic acid and the etiology of endemic (Balkan) nephropathy.

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12129-34. Epub 2007 Jul 9.

5.

Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.

Grollman AP.

Environ Mol Mutagen. 2013 Jan;54(1):1-7. doi: 10.1002/em.21756. Epub 2012 Dec 13. Review.

PMID:
23238808
6.

Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.

Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S.

Environ Mol Mutagen. 2012 Oct;53(8):636-41. doi: 10.1002/em.21732. Epub 2012 Sep 17.

PMID:
22987305
7.

Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.

Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM.

Int J Cancer. 2014 Jul 15;135(2):502-7.

PMID:
24921086
8.

Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.

Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS.

Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013. Epub 2013 Feb 12.

9.

Aristolochic acid-associated urothelial cancer in Taiwan.

Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8241-6. doi: 10.1073/pnas.1119920109. Epub 2012 Apr 9.

10.

p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.

Slade N, Moll UM, Brdar B, Zorić A, Jelaković B.

Mutat Res. 2009 Apr 26;663(1-2):1-6. doi: 10.1016/j.mrfmmm.2009.01.005. Epub 2009 Feb 4. Review.

11.

Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy--an environmental form of the aristolochic acid nephropathy.

Karanović S, Lela IV, Jelaković B, Dickman KG, Peić AK, Dittrich D, Knežević M, Matijević V, Fernandes AS, Miller F.

Kidney Blood Press Res. 2013;37(1):1-8. doi: 10.1159/000343394. Epub 2013 Feb 26.

12.

TP53 Mutational signature for aristolochic acid: an environmental carcinogen.

Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelaković B, Wu L, Truong S, Fernandes A, Grollman AP.

Int J Cancer. 2011 Sep 15;129(6):1532-6. doi: 10.1002/ijc.26077. Epub 2011 Jun 9.

13.

Mutational signature of aristolochic acid: Clue to the recognition of a global disease.

Rosenquist TA, Grollman AP.

DNA Repair (Amst). 2016 Aug;44:205-211. doi: 10.1016/j.dnarep.2016.05.027. Epub 2016 May 20. Review.

PMID:
27237586
14.

Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia.

Grollman AP, Jelaković B.

J Am Soc Nephrol. 2007 Nov;18(11):2817-23. Epub 2007 Oct 17.

15.

Chronic dietary exposure to aristolochic acid and kidney function in native farmers from a Croatian endemic area and Bosnian immigrants.

Jelaković B, Vuković Lela I, Karanović S, Dika Ž, Kos J, Dickman K, Šekoranja M, Poljičanin T, Mišić M, Premužić V, Abramović M, Matijević V, Miletić Medved M, Cvitković A, Edwards K, Fuček M, Leko N, Teskera T, Laganović M, Čvorišćec D, Grollman AP.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):215-23. doi: 10.2215/CJN.03190314. Epub 2015 Jan 13.

16.

The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.

Stiborova M, Frei E, Arlt VM, Schmeiser HH.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):5-11. Review.

17.

Endemic (Balkan) nephropathy is aristolochic acid nephropathy.

Karanović S, Tomić K, Dittrich D, Borovečki F, Zavadil J, Vuković-Lela I, Karlović K, Knežević M, Jelaković B.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014;35(1):43-6. Review.

PMID:
24798595
18.

Balkan endemic nephropathy: an update on its aetiology.

Stiborová M, Arlt VM, Schmeiser HH.

Arch Toxicol. 2016 Nov;90(11):2595-2615. Epub 2016 Aug 19. Review.

19.

Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.

Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ.

Chem Res Toxicol. 2012 May 21;25(5):1119-31. doi: 10.1021/tx3000889. Epub 2012 May 4.

20.

New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor.

Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V.

Mol Nutr Food Res. 2007 Sep;51(9):1131-46.

PMID:
17729220

Supplemental Content

Support Center